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Annular protoﬁbrils (APFs) represent a newly described and distinct class of amyloid structures
formed by disease-associated proteins. In vitro, these pore-like structures have been implicated in
membrane permeabilization and ion homeostasis via pore formation. Still, their formation and rel-
evance in vivo are poorly understood. Herein, we report that APFs are in human Alzheimer’s disease
brain samples and that amyloid-b APFs were associated with activated astrocytes. Moreover, we
show that amyloid-b APFs in astrocytes adopt a conformation in which the N-terminal region is bur-
ied inside the wall of the pore. Our results together with previous studies suggest that the formation
of amyloid-b APFs in astrocytes could be a relevant event in the pathogenesis of Alzheimer’s disease
and validate this amyloidogenic structure as a target for the prevention of the disease.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Alzheimer’s disease (AD), the most common neurodegenerative
disorder, results in the deterioration of selective cognitive perfor-
mance, including memory and mental processing [1]. At the patho-
logical level, the brain of AD patients typically exhibits amyloid-b
(Ab) plaques, intracellular neuroﬁbrillary tangles, vascular amyloi-
dosis, and neuronal and synaptic loss. If the exact contribution of
these individual lesions in the pathogenesis of AD remains contro-
versial, a central role of Ab peptides has been proposed [2]. The cas-
cade of molecular and cellular events, referred to as the amyloid
hypothesis, is thought tobe initiatedby theaccumulationandaggre-
gation of Ab peptides, leading to alterations of synaptic function,
activation of microglia and astrocytes, and oxidative injury. Alto-
gether, these mechanisms lead to the neuronal dysfunction and
degeneration responsible for the cognitive deﬁcits observed in AD.
Ab peptides exist in multiple assembly states: monomers,
oligomers, protoﬁbrils, ﬁbrils, and larger, amorphous aggregates
such as plaques. Soluble oligomers have been implicated as the pri-
mary toxic species in many degenerative diseases in which thechemical Societies. Published by E
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or pathological by different mechanisms [3,4]. However, their
structures, interrelationships with other amyloid aggregates and
exact contribution to disease pathogenesis are not entirely clear
[5–7]. Ab and other amyloidogenic proteins form annular protoﬁ-
brils (APFs) in vitro; these pore-like structures have been observed
in preparations of both oligomers and ﬁbrils [8,9].
The amyloid pore hypothesis [10] suggests that amyloid
oligomers/protoﬁbrils cause cell death by disrupting regulated
membrane permeability, similar in mechanism to bacterial pore-
forming toxins (PFTs) [11–13], which leads to disruption of cellular
ion and protein homeostasis. Membrane permeabilization is a
common pathogenic activity of amyloid oligomers [14], which
are a precursor to APF formation. The formation of APFs is an
attractive explanation for the membrane permeabilization of olig-
omers because of a shared assembly state and the morphological
resemblance between APFs and pores.
Astrocytes are the most abundant cells in the central nervous
system and play an important role in the homeostasis and mainte-
nance of the brain [15,16]. A remarkable feature of astrocytes is
their ability to respond to pathological situations, where they
engage in a series of structural and functional changes collectively
referred to as astrogliosis [17–20].
In an AD patient’s brain, reactive astrocytes are integral
components of neuritic plaques [21,22]. Ab has been detected
within astrocytes surrounding both neuritic and diffuse amyloid
plaques as well as in cultured glial cells [23–28]. In addition, Ablsevier B.V. All rights reserved.
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presence of plaques, since activated astrocytes exhibiting promi-
nent intracellular Ab42 deposits often populate the cortical
molecular layer, even when it is completely devoid of amyloid
plaques [29]. The source of Ab42-positive material that accumu-
lates in astrocytes has not been determined. Two possibilities
exist: either these cells generate Ab42 de novo, or the Ab42
originates from an external source. Several studies indicate that
uptake of Ab is much more likely to be the case [24,27,30]. The
uptake of Ab by astrocytes can be attributed either to their phag-
ocytic capacity [31] or to a receptor-mediated process [32,33].
Furthermore, intracellular Ab is non-ﬁbrillary as indicated by neg-
ative Campbell-Switzer staining and the absence of ﬁbrillary
material at the electron microscopic level [24,34], showing that
intra-astrocytic Ab consists of pre-ﬁbrillar Ab such as monomer,
oligomer, and/or APFs.
Recently, we demonstrated that APFs are on a distinct pathway
from amyloid ﬁbril formation, evading ﬁbrillar fate, and that these
pore-like structures are present in AD human brain intracellularly
and in diffuse plaques [35]. In the present study we show the pres-
ence of Ab APFs in astrocytes in AD brains suggesting, that the
presences Ab in astrocytes is a relevant event in the pathogenesis
of Alzheimer’s disease.Table 1
Subject information from the Research Center Tissue Repository at the University of
California at Irvine Institute for Brain Aging and Dementia.
Brain Age Gender Post mortem interval (hours) Diagnosis
10–02 77 M 4.5 AD
4–02 83 M 3.5 AD
6–00 82 F 3.1 AD
3–02 75 F 4.5 AD
24–00 77 F 3.7 AD
6–91 79 M 5 Ctl
10–99 70 M 5.2 Ctl
16–91 74 F 3.5 Ctl
37–94 81 F 6 Ctl
26–91 86 F 9.5 Ctl2. Materials and methods
2.1. Brain samples
Frozen AD human brain frontal cortex tissues and age-matched
control brain samples were obtained from the Alzheimer’s Disease
Research Center Tissue Repository at the University of California at
Irvine Institute for Brain Aging and Dementia. The following infor-
mation was available for each case: Braak and Braak stage, post-
mortem index, gender, age at death, and Mini-Mental State
Examination score.
2.2. Double immunoﬂuorescence
The sections in parafﬁn were hydrated using xylene, ethanol
100%, ethanol 95%, ethanol 80%, and distilled water. Then the sec-
tions were heated by microwave (750W) in target solution (Dako)
twice for 4 min each. The tissues were washed in 1 PBS, three
times for 5 min each, and blocked for 45 min with 5% horse serum
in PBS. The tissues were incubated overnight with aAPF antibody
(1:350), which speciﬁcally recognizes APF conformation, indepen-
dent of the amino acid sequences [11,35]. After this the sections
were washed three times with 1 PBS for 10 min each wash.
The sections were incubated with the secondary antibody anti-
rabbit Alexa-Fluor 568 (1:700; Molecular Probes, Eugene, OR)
for 60 min. Then the sections were washed three times with PBS
1, for 5 min each, and blocked again with 5% horse serum in
PBS for 30 min. The sections were incubated overnight with one
of the next primary antibodies: Ab-speciﬁc antibody 4G8
(1:800), which recognizes the epitope 17–24; Ab-speciﬁc antibody
6E10 (1:1000), which recognizes the amino terminal epitope
1–16; GFAP antibody (1:1500) which is speciﬁc for astrocytes;
or anti-glutamine synthetase antibody (1:200). The sections were
washed with 1 PBS, three times for 10 min each wash. The sec-
tions were incubated with the secondary antibody anti-mouse
Alexa-Fluor 488 (Molecular Probes) for 60 min. Then the sections
were washed with 1 PBS, three times for 5 min each. Finally, the
sections were incubated with TO-PRO-3 (1:2000; Molecular
Probes) for 5 min to stain the nuclei. Fluorescence images were
visualized using an LSM 510 Meta (Zeiss) laser scanning confocal
microscope.2.3. Quantiﬁcation of activated astrocytes containing annular
protoﬁbrils
Brain samples from ﬁve AD cases were stained with GFAP and
aAPF and viewed with an LSM 510 Meta (Zeiss) laser scanning con-
focal microscope. Ten visual ﬁelds in each sample were randomly
chosen and the numbers of GFAP-positive astrocytes were counted.
Then the percent age of GFAP-positive astrocytes containing annu-
lar protoﬁbrils was determined.
3. Results and discussion
We recently demonstrated by biochemical and immunohisto-
chemical analysis the presence of Ab APFs in AD human brains
[35]. The pathological analysis using the novel antibody aAPF,
which recognizes APF conformation, demonstrated that Ab APFs
are intracellular and extracellular [35]. In the present study further
pathological studies were performed in several AD and age-
matched control subjects (Table 1). Whenever double immunoﬂu-
orescence was performed using aAPF (anti-annular protoﬁbrils)
and 4G8 (anti-Ab), we not only conﬁrmed that Ab annular protoﬁ-
brils are not present in dense amyloid plaques but also for the ﬁrst
time demonstrated the presence of Ab APFs in activated astrocytes
(Fig. 1). To conﬁrm that Ab APFs are also located in activated astro-
cytes, double immunoﬂuorescence using aAPF and GFAP was car-
ried out. In Fig. 2A–F, it is possible to see perfect colocalization
between these two antibodies, conﬁrming the presence of this Ab
structure in activated astrocytes in frontal cortex samples obtained
from AD human brains. Quantiﬁcation analysis demonstrated that
92% of activated astrocytes (positive for GFAP) in the frontal cortex
of AD cases contain Ab annular protoﬁbrils (positive for aAPF) and
only 8% of activated astrocytes do not contain these amyloidogenic
structures (Fig. 2G). This result suggests that some astrocytes are
not activated by Ab and may be activated by a general inﬂamma-
tory response in the area. Another reason could be that annular
protoﬁbrils are inserted into the membranes, making it extremely
difﬁcult to detect them by using antibodies. Double immunoﬂuo-
rescence using aAPF and anti-glutamine synthetase was also per-
formed (Fig. 2H–M). Glutamine synthetase (GS) is an astrocyte-
speciﬁc enzyme that rapidly amidates glutamate to form the
non-neuroactive amino acid glutamine. Glutamine is subsequently
released by astrocytes for uptake by glutamatergic neurons, which
deamidate it when they require glutamate for neurotransmission
[36]. As it is shown in Fig. 2H–M, astrocytes positive for aAPF are
not heavily stained with anti-SG antibody, which agrees with pre-
vious studies that demonstrated a decrease in the expression of SG
in astrocytes in AD patients [37,38]. The authors showed that the
decrease of expression is mostly restricted to the distal process
of the astrocytes, which is conﬁrmed by our results that demon-
strated only partial expression of GS in the astrocyte soma
(Fig. 2J). These previous studies also showed that gliosis is not
Fig. 1. Double staining between anti-Ab antibody 4G8 (green, A, D, and G) and aAPF antibody (red, B, E, and H) conﬁrmed that Ab APFs are located intracellularly and not in
dense amyloid plaques (merge, C, F and I) in AD human brain. Nucleus was stained with TO-PRO-3. Scale bar 10 lm.
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cytes in AD tissue have a normal appearance [37,38], suggesting
that GS-labeled astrocytes and GFAP-labeled astrocytes are mutu-
ally exclusive. This last point is also conﬁrmed by our data where
only the GFAP-positive astrocytes are positive for Ab APF. Double
immunoﬂuorescence using aAPF and anti-glutamine synthetase
was performed in age matched controls (Fig. 2N–P); no annular
protoﬁbrils were detected in astrocytes that were highly positive
for SG.
Several studies demonstrated that most of the Ab in the astro-
cytes are negative for antibodies to the N-terminal-located se-
quences of Ab, including 6E10 (Ab AA 1-17) [30,39]. These
previous studies postulated that there are two possible explana-
tions for the lack of detection of astrocytic Ab with N-terminal
antibodies: either astrocytes produce N-terminal-truncated Ab
on their own or they are capable of taking up extracellular N-ter-
minal-truncated Ab [30,39]. Taking in consideration these earlier
studies, we performed double immunoﬂuorescence with aAPF
and the anti-N-terminal Ab antibody 6E10. The results in Fig. 3
show that Ab APFs in astrocytes are not detected with 6E10. This
suggests that whenever Ab forms this pore-like structure, the
hydrophilic N-terminal sequences of the peptide are not accessi-
ble (fold to the inside part of the pore), leaving the more hydro-
phobic middle and C-terminal regions exposed, thus making thedetection of Ab with antibodies against the N-terminal part
unfeasible.
In the literature there are two possible explanations for the
accumulation of Ab in astrocytes. The ﬁrst possibility is that Ab is
generated in lysosomes from APP within astrocytes [40,41]. Once
Ab accumulation exceeds the capacity of lysosomes, some of the
Ab-containing lysosomes may be released from the cell and be-
come the source of extracellular Ab deposition [42]. The second
possibility is that the astrocytic Ab may originate from extracellu-
lar Ab, although astrocytes are capable of phagocytosis in vivo [43].
Even though the source of generation and/or accumulation of Ab in
astrocytes is not well established, previous studies demonstrated
with exactitude that astrocytic Ab is not ﬁbrillar at the electron
microscopic level [24,34], suggesting that the astrocytes accumu-
lated soluble preﬁbrillar Ab, such as monomers or oligomers. The
data presented in this study conﬁrmed that the Ab in these glial
cells is not ﬁbrillar, and furthermore for the ﬁrst time demon-
strated that Ab adopts a pore-like structure conformation in these
cells.
Recently, Nielsen and colleagues conﬁrmed that astrocytic Ab-
uptake depends on size and/or composition of Ab aggregates as
astrocytes preferentially take up oligomeric Ab over ﬁbrillar Ab.
The authors conclude that astrocytic Ab uptake might be deter-
mined by the conformation and aggregation state of Ab [44,45].
Fig. 2. Active astrocytes accumulated APFs. Confocal laser microscopy of double immunoﬂuorescence with antibodies against glial ﬁbrillary acidic protein, GFAP (green, A and
D) and aAPF (red, B and E) conﬁrmed the presence of these annular structures in active astrocytes (C and F). Quantiﬁcation analysis demonstrated that 92% of GFAP positive
astrocytes in the frontal cortex region of AD cases contained Ab APF (G). Double immunoﬂuorescence staining between anti-SG (green, H and K) and aAPF (red, I and L)
demonstrated that astrocytes positive for APF decrease the expression of SG (J and M). In age-matched controls (N–P), staining with anti-SG (green, N) and aAPF (red, O)
showed that cells were highly positive for SG and no APFs were detected (O). Nucleus was stained with TO-PRO-3. Scale bar 10 lm.
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that oligomers must interact with lipidic membranes to induce the
conversion to APF [11,35], the results presented in the current
study suggest that oligomeric Ab can be taken up by astrocytes
and induce the formation of Ab APFs. Moreover, in another study
it was shown that in mixed astroglial–neuronal cultures Ab peptide
provoked sporadic increase and/or oscillation in cytosolic calcium
½Ca2þi, which lasted for many hours [46,47]. These ½Ca2þi re-
sponses were observed solely in astrocytes and never in neurons
and were generated by Ca2+ inﬂux from extracellular space. Impor-
tantly, astroglial ½Ca2þi ﬂuctuations were somehow linked to neu-
ronal death, which occurred after Ab treatment [46,47]. According
to the authors, an explanation for these results lies in the pore-forming activity of Ab; they suggested that Ab might form trans-
membrane channels that caused dramatic changes in ½Ca2þc sig-
nals in astrocytes. A recent study indicated that Ab
internalization into astrocytes profoundly alter their metabolic
phenotype with deleterious consequences for neuronal viability
[48]. As mentioned above, astrocytes that are positive for APF do
not express SG. Biochemical experiments have shown that Ab
can directly interact with puriﬁed GS protein and reduce the activ-
ity of this enzyme [49,50]. However, it is not clear whether any
opportunities exist for Ab to interact with this enzyme in vivo.
Thus, it has been suggested that the reduction of GS levels in astro-
cytes in Alzheimer’s disease brains could be produced indirectly by
Ab via an oxidation-dependent mechanism [51,52]. According to
Fig. 3. Double staining between anti-Ab antibody 6E10 (green, A and D) and aAPF antibody (red, B and E) show no colocalization between both signals (merge, C and F),
demonstrating that in Ab APFs the N-terminal region is not exposed. Nucleus was stained with TO-PRO-3. Scale bar 10 lm.
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protoﬁbrils in astrocytes and produces several alterations in the
cell, including reactive oxygen species generation, which then
inactivates GS and alters the ‘‘glutamate–glutamine cycle,’’ result-
ing in fatal consequences to the astrocytes and neurons.
According to the previous studies mentioned above and the
observations presented here, we can suggest that in Alzheimer’s
disease, astrocytes take up soluble oligomeric Ab and induce the
formation of Ab APFs. This induces astrocytic alterations with
lethal consequences for neuronal survival. Finally, as has been pre-
viously reported [29,53], astrocytes undergo lysis, resulting in the
formation of small amyloid plaques.
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